Ocena przydatnosci testu z cefpiromem do wykrywania beta-laktamaz o rozszerzonym spektrum u roznych gatunkow paleczek Gram-ujemnych

• Autorzy: Mlynarczyk G. , Mlynarczyk A. , Bilewska A. , Dukaczewska A. , Golawski C. , Kicman A. , Pupek J. , Serafin I. , Luczak M.

Warianty tytułu

EN

High effectiveness of the method with cefpirome in detection of extended-spectrum beta-lactamases in different species of Gram-negative bacilli

• Języki publikacji: PL

Abstrakty

PL

Badano występowanie ESBL u 178 pałeczek Gram-ujemnych, u których wykazano przy zastosowaniu czterech metod: DDST, oraz trzech metod CD (z cefpodoksymem, ceftazydymem i cefotaksymem) wykazano brak wytwarzania ESBL. Zastosowanie metody CD z cefpiromem wykazało, że aż 47,5% z tych szczepów wytwarzało ESBL.

EN

Gram-negative bacilli were examined for ESBL production by using four methods: double-disc synergy diffusion test (DDST), and three tests of combined discs with cefpodoxime, ceftazidime and cefotaxime alone and the same cephalosporins with clavulanic acid. Strains determined as ESBL-nega- tive with all these tests were examined by using fifth method with cefpirome. 47,5% from 178 negative in other methods strains, appeared ESBL-positive in this test. The examined strains belonged to 16 different species. Most of them were Enterobacter cloaceae, Serratia marcescens, Pseudomonas aeruginosa and Acinetobacter baumanii. It seems that the combined discs method with cefpirome may be usefull for phenotypic detection of ESBL producing bacteria also in the case of strains where ESBL production is camouflaged with derepressed chromosomal AmpC beta-lactamases.

Słowa kluczowe

PL

antybiotyki beta-laktamowe; leki przeciwbakteryjne; bakterie Gram-ujemne; beta-laktamaza; cefpirom; metoda CD; Enterobacteriaceae; paleczki Gram-ujemne; wykrywanie

• Wydawca: -
• Czasopismo: Medycyna Doświadczalna i Mikrobiologia
• Rocznik: 2006
• Tom: 58
• Numer: 1
• Opis fizyczny: s.59-65,tab.,bibliogr.

Twórcy

autor

Mlynarczyk G.

• Akademia Medyczna w Warszawie, ul.T.Chalubinskiego 5, 02-004 Warszawa

autor

Mlynarczyk A.

autor

Bilewska A.

autor

Dukaczewska A.

autor

Golawski C.

autor

Kicman A.

autor

Pupek J.

autor

Serafin I.

autor

Luczak M.

Bibliografia

• 1. Ambler RP, Coulson AF, Frere J M i inni. A standard numbering scheme for the class A beta- lactamases. Biochem J 1991; 276: 269-70.
• 2. Andes D, Craig WA. Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect 2005; 11 (Suppl 6): 10-17.
• 3. Baraniak A, Fiett J, Mrówka A, i inni. Evolution of TEM-type extended-spectrum beta-lactamases in clinical Enterobacteriaceae strains in Poland. Antimicrob Agents Chemother 2005; 49:1872-80.
• 4. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-33.
• 5. Carter MW, Oakton KJ, Warner M, Livermore DM. Detection of extended-spectrum beta-lactamases in Klebsiellae with the Oxoid combination disk method. J Clin Microbiol 2000; 38: 4228-32.
• 6. Hadziyannis, E, Tuohy M, Thomas L i inni Screening and confirmatory testing for extended spectrum beta-lactamases (ESBL) in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca clinical isolates. Diagn Microbiol Infect Dis 2000; 36: 113-17.
• 7. Jarlier, V Nicolas MH, FournierG, Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents m Enterobacteriaceae. hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-78.
• 8. Kim J, Lim YM. Prevalence of derepressed ampC mutants and extended-spectrum beta-lactamase producers among clinical isolates of Citrobacter freundii, Enterobacter spp., and Serratia marcescens in Korea: dissemination of CTX-M-3, TEM-52, and SHV-12. J Clin Microbiol 2005; 43: 2452-5.
• 9. Levison, ME. Plasmid-mediated extended-spectrum beta-lactamases in organisms other than Klebsiella pneumoniae and Escherichia coli: a hidden reservoir of transferable resistance genes. Curr Infect Dis Rep 2002; 4: 181-3.
• 10. Medeiros AA. Evolution and dissemination of beta-lactamases accelerated by generations of beta- lactam antibiotics. Clin Infect Dis 1997; 24 (Suppl 1): S19-S45.
• 11. Munoz Bellido J, Garcia-Rodriges JA. Aztreonam-clavulanic acid synergy does not mean extended-spectrum beta-lactamase in Stenotrophomonas maltophilia. J Antimicrob Chemother 1998; 41: 493-4.
• 12. M'Zali, FH, Chanawong A, Kerr KG i inni. Detection of extended-spectrum beta-lactamases in members of the family enterobacteriaceae: comparison of the MAST DD test, the double disc and the Etest ESBL. J Antimicrob Chemother 2000; 45: 881-5.
• 13. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6, 6th ed. National Committee for Clinical Laboratory Standards, Wayne, Pa. 2003.
• 14. Park YJ, Park SY, Oh EJ, i inni. Occurrence of extended-spectrum beta-lactamases among chromosomal AmpC-producing Enterobacter cloacae, Citrobacter freimdii, and Serratia marcescens in Korea and investigation of screening criteria. Diagn Microbiol Infect Dis 2005; 51: 265-9.
• 15. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18:657-86.
• 16. Song W, Moland ES, Hanson ND i inni. Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia. J Clin Microbiol 2005; 43: 4891-4.
• 17. Schwaber, MJ, Raney PM, Rasheed J K i inni. Utility of National Committee for Clinical Laboratory Standards guidelines for identifying extended-spectrum beta-lactamases in non-Escherichia coli and non-Klebsiella spp. of Enterobacteriaceae. J Clin Microbiol 2004; 42: 294-8.